What’s Going On With Tempus AI Stock on Monday?
Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.
Tempus AI stock went up a lot last week, but pulled back today even though good cancer research news came out and the FDA approved its new AI tool for heart disease. When a stock jumps big and then backs up a little, it can mean people are taking profits—that's normal, and it doesn't erase the good news.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.